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Background: Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome
(MCLMR) is a rare autosomal dominant disorder with variable expressivity. It is characterized by mild-to-severe
microcephaly, often associated with intellectual disability, ocular defects and lymphedema. It can be sporadic or
inherited. Eighty-seven patients have been described to carry a mutation in KIF11, which encodes a homotetrameric
motor kinesin, EG5.
Methods: We tested 23 unreported MCLMR index patients for KIF11. We also reviewed the clinical phenotypes of
all our patients as well as of those described in previously published studies.
Results: We identified 14 mutations, 12 of which are novel. We detected mutations in 12 affected individuals, from
6 out of 6 familial cases, and in 8 out of 17 sporadic patients. Phenotypic evaluation of patients (our 26 + 61 earlier
published = 87) revealed microcephaly in 91%, eye anomalies in 72%, intellectual disability in 67% and lymphedema
in 47% of the patients. Unaffected carriers were rare (4 out of 87: 5%). Family history is not a requisite for diagnosis;
31% (16 out of 52) were de novo cases.
Conclusions: All inherited cases, and 50% of sporadic cases of MCLMR are due to germline KIF11 mutations. It is
possible that mosaic KIF11 mutations cause the remainder of sporadic cases, which the methods employed here
were not designed to detect. On the other hand, some of them might have another mimicking disorder and
genetic defect, as microcephaly is highly heterogeneous. In aggregate, KIF11 mutations likely cause the majority, if
not all, of MCLMR.
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Microcephaly with or without chorioretinopathy, lymph-
edema, or mental retardation syndrome (MCLMR, OMIM
152950, ORPHA2526) can occur as a sporadic or inher-
ited (autosomal dominant) disease [1]. MCLMR is charac-
terized by a broad nose, upslanting palpebral fissures, a* Correspondence: miikka.vikkula@uclouvain.be
1Laboratory of Human Molecular Genetics, de Duve Institute, Université
catholique de Louvain, Avenue Hippocrate 74, bte B1.74.06, B-1200 Brussels,
Belgium
13Center for Vascular Anomalies, Cliniques universitaires Saint-Luc, Université
catholique de Louvain, 1200 Brussels, Belgium
Full list of author information is available at the end of the article
© 2015 Schlögel et al. This is an Open Access
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/rounded nasal tip, a long philtrum, a pointed chin, a thin
upper lip, prominent ears, atrial septal defect and lymph-
edema of the dorsum of the feet (pedal œdema) (Figure 1)
[2,3]. Ocular anomalies, the most common of which is
chorioretinal dysplasia, require long-term ophthalmic
follow-up due to slow development. Cerebral magnetic
resonance imaging may reveal a smaller, but usually
structurally normal brain [4,5].
Historically, MCLMR syndrome was divided into two
distinct entities: microcephaly, lymphedema and chorior-
etinal dysplasia syndrome (MLCRD), and chorioretinal
dysplasia, microcephaly and mental retardation syndromearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Figure 1 Clinical characteristics of patients. Clinical features of MCMLR (patients I-10 (A), IX-10 (B), X-10 (C) and XIV-10 (D). Note, broad nose
(A, B), long philtrum (A, B), thin upper lip (A, D), prominent ears (C, D) and bilateral pedal lymphedema (A, B D).
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with MLCRD or CDMMR demonstrated that the pheno-
types are part of a single entity with variable penetrance
and expressivity [6]. KIF11 mutations were also discovered
in 5 families with familial exudative vitreoretinopathy syn-
drome (FEVR), which thus belongs to the phenotypic
spectrum caused by KIF11 mutations [7]. Thirty-one dif-
ferent KIF11 mutations have been described [6-10]. They
include missense, nonsense, frameshift and splice-site mu-
tations distributed across the gene, and are thought to
cause loss-of-function. No genotype-phenotype correlation
has been described. All of the mutations are autosomal-
dominant or de novo; no autosomal recessive case with a
KIF11 mutation has been described.
KIF11 is located on 10q23.33 (http://www.ensembl.org)
and encodes the kinesin family member 11 (also known
as EG5, KNSL1 or TRIP5). EG5 is a 1056-amino-acid
protein, which forms homotetrameric kinesin motor com-
plexes. The N-terminal part composes the motor domain
(Gly16 – Phe363), containing a microtubule-binding
domain that allows sliding along microtubules, an ATP-
binding site with ATPase activity (between residues Gly105and Thr112), and three internal domains that form coiled-
coil structures responsible for multimerization into homo-
tetramers (Figure 2). The C-terminal BimC domain also
plays a role in multimerization [11].
The aim of this study was to screen KIF11 in a large
cohort of patients with signs of MCLMR in order to
identify novel mutations, assess for locus heterogeneity
and genotype-phenotype correlations, and better define
the clinical phenotype associated with KIF11 mutations.
Both sporadic and familial index patients were included,
as well as additional family members when available.
Methods
Patient recruitment
DNA extracted from blood-samples of patients was collected
from different countries (Argentina, Australia, Belgium,
Israel, United-Kingdom, Spain and Sweden). Informed
consent was obtained for all participants, as approved
by the ethical committee of the Medical Faculty at the
Université catholique de Louvain, Brussels, Belgium and
the respective local committees. DNA was extracted
using Wizard genomic DNA purification kit (Promega).
Figure 2 Schematic representation of EG5 (1056 amino acids) with position of mutations causing MCLMR syndrome. Functional domains
(colored), in vitro mutagenized residues (signs) and post-translationally modified amino acids (signs). Mutations found in this study, top; those
published earlier, below (Ostergaard et al. 2012, Hazan et al. 2012, Jones et al. 2013, Mirzaa et al. 2014 and Robitaille et al. 2014). Splice-site
alterations (¶: family II and family V) shown to result in r.211_308del; p.Thr71Argfs*8 and r.789_790insAG; p.Val264Argfs*26, respectively (Figure 4).
N.B. positions based on amino acids in Mirzaa et al.
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been described in case reports [12-14]. Data on certain
phenotypic characteristics, including level of intellectual
disability, were not standardized; evaluation by the re-
ferring clinician was used. The average age of our pa-
tients at the time of conducting the study was 21 years.
Sanger sequencing of KIF11
To screen for KIF11 mutations, the 22 exons and their
corresponding splice-sites were amplified, as described
[6]. Purity and size of amplicons were evaluated by agarose
gel electrophoresis using GeneRuler™ 100 bp (Thermo
Scientific) DNA size ladder. Direct sequencing was per-
formed on a 3130xl Genetic Analyzer (Life Technolo-
gies). All sequences were analyzed with CLC Main
Workbench 6© (CLC Bio), using reference sequence
NG_032580.
Mutation analysis
Mutations were named according to the guidelines of the
Human Genome Variation Society (http://www.hgvs.org/
mutnomen/), verified using Mutalyzer (https://mutaly-
zer.nl/) [15]. The mutations have been submitted to the
Vascular Anomaly and Lymphedema Mutation Data-
base (www.icp.ucl.ac.be/vikkula/VAdb). The dbSNP137
(http://www.ncbi.nlm.nih.gov/projects/SNP/) [16], 1000Ge-
nomes (http://browser.1000genomes.org), ESP6500 (http://
evs.gs.washington.edu/EVS/), and GoNL databases (http://
www.nlgenome.nl) of genomic variants were searched for
each mutation identified, in order to eliminate any
polymorphisms. The effects of amino acid changes onprotein function were predicted using PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/) [17] and SIFT (http://
sift.jcvi.org/www/SIFT_enst_submit.html) [18]. Mutation-
Taster (http://www.mutationtaster.org/) [19] was used to
detect potential splice-site changes. When DNA from
additional family members was available, co-segregation
of mutation with disease was assessed. If the mutation was
not identified in either parent, the Powerplex HS16
genotyping kit (Promega) on a 3130xl Genetic Analyzer
(Life Technologies) was used to confirm paternity and
maternity.
Evaluation of splicing abnormalities associated with
intronic mutations
RNA was extracted from EBV-transformed lymphoblasts
or lymphocytes with TriPure (Roche) (patients II-10 and
V-12 and 2 controls) and retro-transcribed using RevertAid
H Minus First Strand cDNA Synthesis Kit (Fermentas) with
random hexamers. For patient II-10 and a control, PCR-
amplification was performed using primers 5’-GAGGA
TTGGCTGACAAGAGC and 5’-CGTGGAATTATACCA
GCCAAG. After agarose gel electrophoresis, bands were
extracted using QIAquick® Gel Extraction Kit (QIAGEN)
and purified amplicons were sequenced and compared to
the reference sequence NM_004523.3. For patient V-12
and controls, amplicons were generated with 5’-GGTTTA
GAAGAAATTACAGTACAC and 5’-TGACCCTTCCCAA
AGTCAAC. They were cloned into the pCR-II TOPO vec-
tor (Invitrogen) according to the manufacturer’s protocol
and the plasmids were transfected into JM109 competent
bacteria (Promega, Madison, WI, USA) by heat shock. For
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and inserts were PCR-amplified and sequenced using the
same primers (above).
Results
Sequencing of the 22 coding exons of KIF11 and their
flanking splice-sites identified fourteen heterozygous
mutations in the 23 index patients (Table 1 and Figure 2).
All patients with family history (n = 6) had a mutation.
These germline variants included two nucleotide substitu-
tions and one single nucleotide deletion; all result in pre-
mature stop codons. Three splice-site alterations were
also identified. The changes co-segregated with phenotype
in the five families for which we had additional samples
(n = 20) (Table 1 and Figure 3).
Among the 17 sporadic patients, we found eight with
a mutation in KIF11: one nonsense, four frameshifts and
two canonical consensus splice-site changes (Table 1)
that we consider pathogenic; and one missense alteration
that we regarded as probably pathogenic, but requiring
further functional validation (Table 1). DNA from par-
ents was available for 7 of the 8 sporadic patients with a
KIF11 mutation. All appeared to be de novo changes
(100%) (Figure 3) absent in both parents, representing
41% (n = 7/17) of all our sporadic cases. In total, 30% of
all the index cases studied (7/23) had de novo KIF11
mutations.
The mutations detected most likely result in loss of
function of KIF11 due to nonsense-mediated mRNA
decay or premature truncation of the protein (n = 13).
Lymphoblast RNA from a patient with a splice-site alter-
ation (Patient II-10: c.308+1G>T) showed skipping of
exon 3 (r.211_308del) (Figure 4A), leading to a change
in reading frame (p.Thr71Argfs*8) (Figure 4B). The mu-
tant transcript was expressed at a lower level than the
wild-type allele, suggesting mRNA loss by nonsense-
mediated mRNA decay. In patient V-12, the splice-variant
(c.790-3A>G) generates a new AG-acceptor site-like se-
quence. In lymphocytes, this led to the insertion of 2 nu-
cleotides from the intronic splice site (r.789_790insAG)
into the mRNA (Figure 4C and D), causing a reading
frame shift and appearance of a premature stop codon 26
amino acids after (p.Val264Argfs*26). We identified only 1
mutation leading to a heterozygous amino acid substitu-
tion: Tyr82Phe (Patient I-10). The substitution occurs at a
highly conserved amino acid position in the kinesin motor
domain from fish to human being. It is predicted to alter
protein function by PolyPhen-2, SIFT and Mutation Taster
2.0. The change is absent in the 1000Genomes, ESP6500,
and GoNL databases.
Taking into account all the patients found to carry a
mutation in this study (n = 26), as well as the 61 already
reported [6-10], microcephaly was present in 79/87 pa-
tients (91%), eye anomalies in 63/87 patients (72%),intellectual disability in 58/87 (67%) and lymphedema in
41/87 patients (47%). Average SD for microcephaly was
−5,1 (ranging from −1,1 to −9,5), on the basis of 64 pa-
tients with published data. None of the clinical signs was
fully penetrant. Atypical features including cerebral and
cardiac anomalies were present in 48 patients (55%).
Taking all index patients with mutations into account
(n = 52), sporadic cases represent 42% (22/52). It has
been proven in 73% (16/22) of them that the mutation
appeared de novo.
The nine KIF11 mutation-negative sporadic patients
were included in KIF11 mutation screening due to the
presence of signs and symptoms corresponding to
MCLMR. However, certain patients showed additional
features, not described for MCLMR: hydrops fetalis and
lymphangiectasia (1 patient: XX-10), motor delay (2
patients: XVIII-10, XXIII-10), and Madelung deformity
(1 patient: XIX-10). These patients probably reflect the
clinical and genetic variability of microcephaly syndromes.
Discussion
We discovered 14 KIF11 mutations, 12 of which are
novel, in 26 MCLMR patients (Figure 2). A mutation
was detected in all patients with a family history of
MCLMR, similar to previously reported series [6-10].
We also discovered a heterozygous germline de novo
mutation in 7 sporadic patients and in 1 patient without
family history of MCLMR, but for whom no parental
DNA was available for testing. Thus, 87,5% of our spor-
adic patients with a KIF11 mutation had a proven de
novo mutation. This represents 41% (7/17) of sporadic
index patients in this study. Taking into account all
index patients with a KIF11 mutation, sixteen sporadic
patients have been reported to have a de novo mutation
(7 in the current study, and 9 in previously published
works), indicating that KIF11 has a high de novo muta-
tion rate: 16 de novo/52 mutation-positive index pa-
tients; i.e. 31% across studies. Several de novo mutations
have also been identified in other genes mutated in
microcephaly (i.e. CTNNB1 [20] and TUBA1A [21]) and
in primary lymphedema, such as SOX18, FOXC2 and
VEGFR3 [22-24].
No KIF11 mutation-negative familial cases were iden-
tified; however, about half of the sporadic cases were
KIF11 mutation-negative. These may be explained by
several hypotheses: (1) Deletions or deep-intronic muta-
tions in KIF11, which were not assessed in the study; (2)
Somatic/mosaic KIF11 mutations that are not detectable
in the blood by Sanger sequencing: mosaicism as a cause
of MCLMR can be investigated by sequencing tissue and
blood-DNA using targeted deep sequencing; (3) Exist-
ence of a mimicking disorder: many different genes can
cause microcephaly, including those implicated in auto-
somal recessive primary microcephaly and syndromic
Table 1 Clinical features of MCLMR patients presented in order of mutation position in KIF11
Patient Reference Nucleotide
variant
NM_004523.3
Exon Protein
alteration
Inheritance Microcephaly
(SD)
Eye changes Lymphedema Intellectual
disability
Additional clinical features Phenotype
or the same
mutation
described in
Patients with mutation
I-10 LE-401-10 c.245A>T 3 p.(Tyr82Phe) de novo −7.0 Chorioretinitis Feet Severe Severe sensorineural hearing
loss, proteinuria, upslanting
palpebral fissures, broad nose
with rounded tip, anteverted
nares, long philtrum with thin
upper lip and pointed chin
-
II-2 LE-09-2 c.308+1G>T 3 p.(Thr71Argfs*8) AD −4.0 Normal
electroretinography
but discrete
narrowing of blood
vessels
- - - -
II-10 LE-09-10 c.308+1G>T 3 p.(Thr71Argfs*8)¶ AD −3.0 Retinal dystrophy Mild Moderate Scoliosis -
III-10 LE-448-10 c.436A>T 5 p.(Lys146*) AD −4.4 Bilateral persistent
hyperplastic primary
vitreous, bilateral
retinal detachment,
bilateral glaucoma
and inoperable retinal
detachment right eye
Feet - Lensectomy, vitrectomy right
eye and long philtrum
-
IV-1 LE-152-1 c.630del 6 p.(Tyr211Ilefs*4) AD −2.5 - + - - -
IV-10 LE-152-10 c.630del 6 p.(Tyr211Ilefs*4) AD −5.9 Retinal dystrophy Mild Moderate Facial dysmorphism -
IV-11 LE-152-11 c.630del 6 p.(Tyr211Ilefs*4) AD −5.9 Unknown, wears
glasses
- Moderate Facial dysmorphism -
V-1 LE-114-1 c.790-3A>G 8 p.(Val264Argfs*26) AD Within normal
limits
- - - - -
V-11 LE-114-11 c.790-3A>G 8 p.(Val264Argfs*26) AD −2.2 Microphthalmos - - - -
V-12 LE-114-12 c.790-3A>G 8 p.(Val264Argfs*26)¶ AD −2.9 Bilateral falciform
retinal folds,
microphthalmos,
visual deficit and
glaucoma
Feet as a child Moderate Sloping forehead Young ID.,
et al., 1987
V-100 LE-114-100 c.790-3A>G 8 p.(Val264Argfs*26) AD −6.6 Falciform retinal folds Hands and feet Moderate Clinodactyly and facial
dysmorphism
-
V-101 LE-114-101 c.790-3A>G 8 p.(Val264Argfs*26) AD −2.3 - - Mild Left Club foot and dyslexia -
VI-10 LE-103-10 c.1985T>A 15 p.(Leu662*) AD −5.0 Bilateral retinal
degeneration
Feet Mild - -
VI-2 LE-103-2 c.1985T>A 15 p.(Leu662*) AD - - Mild Mild - -
VII-10 LE-411-10 c.2005del 16 p.(Glu669Lysfs*7) de novo −3v8 Retinal dystrophy - Moderate Pachygyria -
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Table 1 Clinical features of MCLMR patients presented in order of mutation position in KIF11 (Continued)
VIII-10 LE-125-10 c.2160+1G>A 16 Altered Splicing de novo −9.2 + + Moderate Constipation and facial
dysmorphism
-
IX-10 LE-406-10 c.2244_2247dup 17 p.(Val750*) Sporadic −3.0 Persistent hyperplastic
primary vitreous
posterior and retinal
atrophy
Feet Moderate Facial dysmorphism -
X-10 LE-413-10 c.2304_2305del 18 p.(His768Glnfs*7) de novo −5.4 Retinal dystrophy - Severe - Ostergaard
P., et al.,
2012
XI-10 LE-08-10 c.2547+2T>C 18 Altered Splicing AD −7.3 Subtle atrophic
pigment epithelial
changes temporally
from the optic disc on
the right eye and
atrophic changes
prominent on the left
eye
- Moderate - Ostergaard
P., et al.,
2012
XI-13 LE-08-13 c.2547+2T>C 18 Altered Splicing AD −4.4 Unknown - Moderate Nasal speech and
micrognathia
Ostergaard
P., et al.,
2012
XI-100 LE-08-100 c.2547+2T>C 18 Altered Splicing AD −8.3 Microphthalmia,
chorioretinopathy and
retinal dystrophy
Feet Moderate Syndactyly, cardiopathy,
pachygyria and facial
dysmorphism
Casteels I.,
et al., 2001,
Ostergaard
P., et al.,
2012
XI-101 LE-08-101 c.2547+2T>C 18 Altered Splicing AD −4.5 Bilateral corioretinal
dystrophy
+ Moderate - Ostergaard
P., et al.,
2012
XI-102 LE-08-102 c.2547+2T>C 18 Altered Splicing AD −3.5 - Peri-oral Moderate Micrognathia, full nose tip,
diathema of teeth and
dysplastic ears
Ostergaard
P., et al.,
2012
XII-10 LE-414-10 c.2723dup 19 p.(Leu909Alafs*2) de novo −5.5 Retinal dystrophy + Severe - Fryns JP.,
et al., 1995
XIII-10 LE-415-10 c.2782_2783dup 20 p.(Gln928Hisfs*13) de novo −3.8 Chorioretinal atrophy - Moderate - -
XIV-10 LE-104-10 c.2922G>A 20 Altered Splicing de novo −5.3 Myopic chorioretinal
dysplasia
Hands and
feet
- Fairly broad nasal root,
prominent ears and a narrow
palate
-
Patients without a mutation
XV-10 LE-87-10 No mutation - - Sporadic −6.9 Bulls eye maculopathy Acute oedema
at birth,
resolved;
bilateral
lymphedema
persisted
Severe Hearing loss-bilateral
sensorineural and facial
dysmorphism
-
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Table 1 Clinical features of MCLMR patients presented in order of mutation position in KIF11 (Continued)
XVI-10 LE-88-10 No mutation - - Sporadic −8.1 Bilateral Falciform
retinal folds
Mild, feet as a
child
Moderate Epilepsy and facial
dysmorphism
-
XVII-10 LE-90-10 No mutation - - Sporadic −4.6 - + - Lissencephaly, coronal
craniosynostosis and ADHD
-
XVIII-10 LE-91-10 No mutation - - Sporadic −3.9 - Feet and legs Mild Mild hypoplastic aortic arch,
secundum atrial septal defects,
mild motor delay, mild speech
delay, ADHD and hyperlaxity
-
XIX-10 LE-121-10 No mutation - - Sporadic −3.0 - Legs and face Moderate ADHD on methylphenidate
treatment, hyperlaxity, bilateral
Madelung deformity and egg
allergy
-
XX-10 LE-393-10 No mutation - - Sporadic −5.0 Blind Lower limbs Severe Cerebral atrophy,
encephalopathy, cervicofacial
lymphatic malformations,
chylothorax, pleural effusion,
hydrops fetalis and intestinal
lymphangiectasia
-
XXI-10 LE-412-10 No mutation - - Sporadic −2.1 - Feet Moderate Pectus excavatum, epicanthic
folds and small ears
-
XXII-10 LE-417-10 No mutation - - Sporadic −4.4 Retinal dystrophy - Servere Epilepsy -
XXIII-10 LE-428-10 No mutation - - Sporadic −10.0 Chorioretinal
dysplasia, myopia,
nystagmus
horizontale ODG
Mild Severe Arterial pulmonary
hypertension, atrio-ventricular
complete canal, motor delay,
simplified gyral pattern, autistic
behavior, ADHD, small for
height (−4DS) and weight
(−4DS), and facial
dysmorphism.
-
+= present, −= absent, AD = autosomal dominant, ¶ =mRNA tested, ADHD=Attention deficit hyperactivity disorder.
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Microcephaly
Eye changes
Lymphedema
Intellectual disability
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10 10 10 10 10 1010 1010
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p.Leu662*
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21
*
*
II
c.308+1G>T
10
21
*
*
V
c.709-3A>G
*
**
**
11 12 13
100 101
21
III
p.Lys146*
*
10
IX
p.Val750*
10
*
I 
p.Tyr82Phe
10
21
*
XIV
c.2922G>A
10
21
*
VIII
c.2160+1G>A
10
21
*
VII
p.Gln669Lysfs*7
10
21
*
X
p.His768Gln*7
10
21
*
10
XII
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21
*
21
XIII
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*
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10
100 102101
1311 12 14
*
* * *
*
IV
p.Tyr221Ilefs*4
10
21
*
11
* *
XVII IIIXXIIXXIXXIVX XVIII XXXIX
Figure 3 Pedigrees and phenotypes of screened patients. Upper panel, KIF11 mutation-positive; lower panel, KIF11 mutation-negative. Individuals
with a bar, clinically examined; those with a number, sequenced. Patients with a star have a mutation.
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presence of motor delay in patients XVIII-10 and XIII-
10 may suggest Cohen syndrome (OMIM 216550) [27].
The Madelung deformity and hydrops fetalis observed in
two other patients may also be indicative of a distinct
syndrome, as they have never been described in
MCLMR. Eight out of nine of our negative cases had
microcephaly and lymphedema; (4) Novel genetic cause
for MCLMR in mutation-negative patients. Overall, our
results suggest that KIF11 is the major causative gene
for MCLMR, with no evidence of locus heterogeneity in
familial cases.
The most frequent clinical signs and symptoms in pa-
tients with a KIF11 mutation are microcephaly (91%),
eye anomalies (72%) and intellectual disability (67%)
(Figure 3 and Table 1). MCLMR patients may have a
structurally abnormal brain i.e. pachygyria (Table 1: Pa-
tients VII-10 & XI-100) [9]. Lymphedema is present in
47% of mutation-positive patients (Table 1).
Although none of the individual symptoms is fully
penetrant, the overall penetrance of MCLMR is high
(83/87; 95%). Only 4 asymptomatic mutation carriers
have been identified amongst 87 individuals tested. Pa-
tients in the same family (Family II, IV, V, VI, and XI),
with the same mutation may however have different
phenotypes, demonstrating variable expressivity.The 44 mutations identified so far in KIF11 (nine mis-
sense, twenty-five premature stop codons and ten splice-
site changes) are scattered across the length of gene
(Figure 2). There are no clear phenotypic differences be-
tween missense mutation carriers and those with prema-
ture stop codon mutations. As the most 5’ premature
truncation codon occurs at the very 5’ end (amino acid
47), and lymphoblasts had a significantly lower expression
of the mutant allele of patient II-10 (c.308+1G>T), all mu-
tations most likely cause loss of EG5 function.
KIF11 mutations have pleiotropic effects with variable
penetrance. One possible explanation could be the oc-
currence of somatic second-hit mutation(s), as we have
proven for glomuvenous malformation [28,29] and
mucocutaneous venous malformation [30]. Random
somatic changes inevitably occur in the cells of all indi-
viduals, and result in a double-hit situation in some
cells in patients with a germline mutation. The result-
ing phenotypes would depend on the types and devel-
opmental stages of cells affected.
There are nine amino acid substitutions identified in
MCLMR patients. One of them affects the initiating me-
thionine at position 1 (p.Met1Thr) most likely causing
non-translation of KIF11. Seven of the remaining eight
amino acid substitutions occur in the kinesin motor domain
(p.Tyr82Phe, p.Phe144Leu, p.Arg221Gly, p.Arg234Cys,
exon 2 exon 3 exon 4*
c.308+1G>T
BA
Exon 3 skipping
r.211_308del : p.Thr71Argfs*8 
300 bp
200 bp
100 bp
C
r.789_790insAG : p.Val264Argfs*26
exon 8exon 7
exon 8exon 7
D
exon 8exon 7
exon 2 exon 4
wt
Patient 
V-12
wt
   Patient      
Ladder   II-10       c1           c2
Patient 
V-12
Figure 4 Effect of splice site mutations. (A) RT-PCR using primers in exon 2 and 5 on cDNA from patient II-10 (c.308+1G>T) and two controls
(c1 and c2). Wild-type amplicon, 250 bp; mutant, 152 bp. (B) (Sequencing of lower band unraveled skipping of exon 3 resulting in a premature
stop-codon (r.211_308del: p.Thr71Argfs*8). (C) Sequencing of cDNA of patient V-12 (c.790-3A>G) for an amplicon covering exon 7/8 splice site
revealed double-sequence. (D) Sequencing of cloned amplicon fragments revealed insertion of 2 nucleotides (AG) from the intronic acceptor site
(r.790_791insAG) in mutant clones. This leads to a premature stop-codon (p.Val264Argfs*26).
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last one in the BimC Box (p.Arg944Cys), implicated in
multimerization (Figure 2). Both domains have been
shown to be important for KIF11 function during mi-
tosis [11]. The kinesin motor domain contains amino
acids important for tertiary structure. Arg234 makes a
salt bridge with Glu270 to close the active site essential
for ATP hydrolysis [31]. Substitution of Arg234 for a
cysteine likely perturbs closure of the pocket and ATP
hydrolysis. The impact of Ser235Cys is likely similar
due to its vicinity to Arg234. In addition, the serine-to-
cysteine change would affect polarity and thus modify the
stabilization of a molecule of water in the nucleotide-
binding pocket. Moreover, in the 3D structure (PDB ID:
3hqd), Arg221 is located in front of Ser235. Substitution
for glycine could influence the structure of the nucleotide-
binding pocket. Tyr82, Phe144 and Glu344 are located in
an alpha-helix and His244 in a central beta-sheet in the
kinesin domain. It is unclear whether these mutations,
and the BimC Box mutation, affect stability, structure
and/or function.In vitro mutagenesis (Pro131Ala, Thr926Ala and
Ser1033Ala) showed that the N-tail and the BimC do-
main are important for intra-cellular localization of the
protein [32]. Thr926 of the BimC domain is phosphor-
ylated by CDK1 (Cyclin-dependent kinase 1), whereas
Ser1033 is partially phosphorylated by NEK6 (Never in
mitosis gene a -related kinase 6). Phosphorylation of
these sites is important for the mitotic function of EG5
[33,34]. Depletion of KIF11 causes mitotic arrest. This
can be rescued by re-expression of the protein, but not
by a Thr926Ala mutant, which lacks the ability to interact
with microtubules [33]. The Arg944Cys mutation likely
causes dysfunction of this same domain.
EG5 is a plus end-directed microtubule motor. It con-
tributes to the establishment and maintenance of bipolar
spindles during mitosis and meiosis that push the poles
apart [35]. This is required for the separation of dupli-
cated centrosomes. EG5 is considered as a slow kinesin,
which slows down the spindle separation during mitosis.
It is dispersed in the cytoplasm during the interphase,
regroups at the spindle poles during prophase and stays
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expressed in proliferative tissues. Disruption by homozy-
gous deletion of Kif11 in mice resulted in embryonic le-
thality due to defective implantation in the uterine wall
[36]. Microcephaly, ocular anomalies and œdema were
not reported in heterozygous embryos. Morpholino-based
knock-down of Kif11 also led to embryonic lethality, or se-
vere œdema and circulation defects [37]. Inhibition of
EG5 by dimethylenastron (DMN) or ispinesib diminished
endothelial cell proliferation (HUVEC, hCMEC/D3 and
LEC) and embryonic angiogenesis [37].
EG5 disruption is implicated in neuronal development
and the phenotype observed in MCLMR adds KIF11 to
the long list of genes implicated in intellectual disability.
Inhibition of EG5 in cultures of synaptic neurons led to
faster growth of axons, with an abnormal maturation
[38]. Intellectual disability due to EG5 dysfunction could
thus be explained by neuronal inability to grow and/or
to connect correctly. The etiopathogenesis of the eye
anomalies could be due to defective neurogenesis or
angiogenesis.
EG5 could cause lymphedema by a microtubule-
dependent function in trafficking the major lymphangio-
genic tyrosine kinase receptor, VEGFR3, in endocytotic
vesicles [39]. On the other hand, it could be that the endo-
thelial cell function of EG5 is independent of the kinesin-
motor domain, as is the case for KIF26A (kinesin family
member 26A), KIF4 (kinesin family member 4A/B) and
MAP2 (microtubule-associated protein 2) [40-42]. In fact,
EG5 plays also a role in protein translation [43]. The ex-
pression of KIF11 in LECs is regulated by FOXC2, a major
lymphangiogenic transcription factor [44]. It is however
not known if MCLMR patients have lymphatic hyperpla-
sia as observed in FOXC2-mutated patients (lymph and
venous reflux and failure or absence of lymphatic and ven-
ous valves) or hypoplasia as seen in VEGFR3-mutation
caused Nonne-Milroy lymphedema [45,46]. Lymphoscinti-
graph of one MCLMR patient showed no significant
main-tract filling suggesting a peripheral lymphatic-vessel
dysfunction [6].
Conclusions
KIF11 mutations are identified in all familial cases of
MCLMR. De novo mutation rate is high for KIF11: 16
out of 22 (73%) sporadic cases. Mutations most likely cause
loss of EG5 function. There is no genotype-phenotype cor-
relation. The phenotype of the KIF11 mutation-negative
sporadic patients may be due to non-detected germline
or mosaic KIF11 mutations and/or defects in (a) gene(s)
causing (a) mimicking disorder(s), as microcephaly and
primary lymphedema are genetically highly heteroge-
neous. A better elucidation of the pathophysiological
mechanisms is needed to enable development of tar-
geted therapies for MCLMR.Availability of supporting data
The mutations were submitted to the Vascular Anomaly
and Lymphedema Mutation Database (www.icp.ucl.ac.be/
vikkula/VAdb).
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